BRPI0720232A2 - Produto de cloridrato de oximorfona, formulação farmacêutica, método para purificar cloridrato de oximorfona, e, produto de cloridrato de oximorfona - Google Patents

Produto de cloridrato de oximorfona, formulação farmacêutica, método para purificar cloridrato de oximorfona, e, produto de cloridrato de oximorfona

Info

Publication number
BRPI0720232A2
BRPI0720232A2 BRPI0720232-6A2A BRPI0720232A BRPI0720232A2 BR PI0720232 A2 BRPI0720232 A2 BR PI0720232A2 BR PI0720232 A BRPI0720232 A BR PI0720232A BR PI0720232 A2 BRPI0720232 A2 BR PI0720232A2
Authority
BR
Brazil
Prior art keywords
oxymorphone
chloride
chloride product
product
purifying
Prior art date
Application number
BRPI0720232-6A2A
Other languages
English (en)
Inventor
Jen-Sen Dung
Erno M Keskeny
James J Mencel
Original Assignee
Johnson Matthey Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37712066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0720232(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Johnson Matthey Plc filed Critical Johnson Matthey Plc
Publication of BRPI0720232A2 publication Critical patent/BRPI0720232A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0720232-6A2A 2006-12-14 2007-12-14 Produto de cloridrato de oximorfona, formulação farmacêutica, método para purificar cloridrato de oximorfona, e, produto de cloridrato de oximorfona BRPI0720232A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0624880.1A GB0624880D0 (en) 2006-12-14 2006-12-14 Improved method for making analgesics
PCT/GB2007/050758 WO2008072018A1 (en) 2006-12-14 2007-12-14 Improved method for making analgesics

Publications (1)

Publication Number Publication Date
BRPI0720232A2 true BRPI0720232A2 (pt) 2013-12-24

Family

ID=37712066

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720232-6A2A BRPI0720232A2 (pt) 2006-12-14 2007-12-14 Produto de cloridrato de oximorfona, formulação farmacêutica, método para purificar cloridrato de oximorfona, e, produto de cloridrato de oximorfona

Country Status (13)

Country Link
US (1) US7851482B2 (pt)
EP (1) EP2102213A1 (pt)
JP (2) JP4786748B2 (pt)
CN (2) CN101652371A (pt)
AU (1) AU2007331223B2 (pt)
BR (1) BRPI0720232A2 (pt)
CA (1) CA2672644A1 (pt)
GB (1) GB0624880D0 (pt)
MX (1) MX337864B (pt)
NO (1) NO20092503L (pt)
RU (1) RU2422445C2 (pt)
WO (1) WO2008072018A1 (pt)
ZA (1) ZA200904317B (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
CA2644095A1 (en) * 2006-03-02 2007-09-13 Mallinckrodt Inc. Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
EP2073636B1 (en) * 2006-10-17 2012-09-05 Penick Corporation Process for preparing oxymorphone
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
JP2010522189A (ja) * 2007-03-23 2010-07-01 マリンクロッド・インコーポレイテッド オリパビンからのオキシモルホンの改善された調製
WO2008130553A1 (en) * 2007-04-16 2008-10-30 Mallinckrodt Inc. Novel opiate reduction utilizing catalytic hydrogen transfer reaction
FR2923484B1 (fr) * 2007-11-09 2012-11-09 Sanofi Aventis Procede de preparation de composes morphiniques
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
LT2273983T (lt) 2008-05-09 2016-10-25 Grünenthal GmbH Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija
EP2456427B1 (en) * 2009-07-22 2015-03-04 Grünenthal GmbH Hot-melt extruded controlled release dosage form
AU2010275754B2 (en) 2009-07-22 2014-05-15 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive opioids
EP2580218B1 (en) 2010-06-11 2015-02-25 Rhodes Technologies Process for n-dealkylation of tertiary amines
CA2936749C (en) 2010-06-11 2019-07-09 Joshua R. Giguere Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
US8563571B2 (en) 2010-07-22 2013-10-22 Noramco, Inc. Crystalline forms of oxymorphone hydrochloride
EP2420503A1 (en) * 2010-07-27 2012-02-22 Universität Innsbruck Process for the synthesis of 14-oxygenated morphinan-6-ones
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
MX2013002293A (es) 2010-09-02 2013-05-09 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
WO2012151669A1 (en) 2011-05-06 2012-11-15 Brock University Process for the preparation of morphine analogs via metal catalyzed n-demethylation/functionalization and intramolecular group transfer
CA2837233A1 (en) 2011-05-27 2012-12-06 Grunenthal Gmbh Crystalline, anhydrous forms of oxymorphone hydrochloride
LT2736497T (lt) 2011-07-29 2017-11-10 Grünenthal GmbH Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
AU2013248351B2 (en) 2012-04-18 2018-04-26 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9657029B2 (en) 2012-06-11 2017-05-23 Siegfried Generics International Ag Method of preparing oxymorphone
MX362838B (es) 2012-07-12 2019-02-19 SpecGx LLC Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
AR091779A1 (es) 2012-07-16 2015-02-25 Rhodes Technologies Procedimiento para la sintesis mejorada de opioides
AR092858A1 (es) 2012-07-16 2015-05-06 Rhodes Tech Procedimiento para una sintesis mejorada de opioide
CN103113378B (zh) * 2013-02-20 2016-04-06 北京华素制药股份有限公司 一种盐酸羟吗啡酮的合成方法
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
CA2907950A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
EA032465B1 (ru) 2013-07-12 2019-05-31 Грюненталь Гмбх Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
GB201313211D0 (en) 2013-07-24 2013-09-04 Cambrex Karlskoga Ab New process
CN105452253A (zh) * 2013-08-02 2016-03-30 庄信万丰股份有限公司 用于制备氢羟吗啡酮的方法
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
AU2015207734B2 (en) 2014-01-15 2017-02-23 Rhodes Technologies Process for improved oxymorphone synthesis
JP2017502991A (ja) 2014-01-15 2017-01-26 ローズ テクノロジーズ 改良されたオキシコドン合成のための方法
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
WO2016005923A1 (en) * 2014-07-09 2016-01-14 Rhodes Technologies Reduction of alpha, beta-unsaturated ketone levels in morphinan derivative compositions
US20160052932A1 (en) * 2014-08-25 2016-02-25 Johnson Matthey Public Limited Company Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
AU2016251854A1 (en) 2015-04-24 2017-10-19 Grunenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US20160340362A1 (en) * 2015-05-20 2016-11-24 Noramco, Inc. Process For The Preparation Of Oxymorphone Freebase
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
ES2701855T3 (es) 2016-05-31 2019-02-26 Alcaliber Investig Desarrollo E Innovacion Slu Proceso para la obtención de 3,14-diacetiloximorfona a partir de oripavina
EP4122933A1 (en) * 2017-06-20 2023-01-25 Johnson Matthey Public Limited Company Hydrogenation process for preparing oxycodone hydrochloride from 14-hydroxycodeinone

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB717008A (en) * 1951-05-29 1954-10-20 Mozes Juda Lewenstein Morphine derivative
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
GB1317210A (en) 1970-12-11 1973-05-16 Macarlan Smith Ltd Reduction of thebaine
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
FR2636330B1 (fr) 1988-09-13 1990-11-30 Sanofi Sa Procede de preparation de derives de morphinane
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
IL107400A0 (en) * 1992-11-10 1994-01-25 Cortech Inc Bradykinin antagonists
US6291675B1 (en) 1996-05-21 2001-09-18 The United States As Represented By The Department Of Health And Human Services Methods of o-demethylation and n-deprotection
US6067749A (en) 1996-07-11 2000-05-30 Tasmanian Alkaloids Pty. Ltd. Papaver somniferum strain with high concentration of thebaine and oripavine
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
GB9713703D0 (en) 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
GB9717629D0 (en) 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
US6177567B1 (en) 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
KR20030048026A (ko) 2001-07-06 2003-06-18 펜웨스트 파머슈티칼즈 컴파니 옥시모르폰의 서방형 제제
WO2003004031A1 (en) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
US7973064B2 (en) * 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US6864370B1 (en) 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
CA2539659C (en) 2003-09-22 2013-03-26 Johnson Matthey Public Limited Company Process for the synthesis of morphinane compounds and intermediates thereof
US7875718B2 (en) 2003-09-22 2011-01-25 Johnson Matthey Public Limited Company Process for the synthesis of morphinane compounds and intermediates thereof
TWI483944B (zh) 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US6949645B1 (en) 2004-05-20 2005-09-27 Acura Pharmaceuticals, Inc. Process for the production of opiates
GB2429206A (en) 2004-07-09 2007-02-21 Tasmanian Alkaloids Pty Ltd Process for the synthesis of hydromorphone
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
WO2006084389A1 (de) * 2005-02-11 2006-08-17 Cilag Ltd. Verfahren zur reinigung von noroxymorphon-verbindungen
CA2644095A1 (en) 2006-03-02 2007-09-13 Mallinckrodt Inc. Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
US20080125592A1 (en) 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine

Also Published As

Publication number Publication date
AU2007331223B2 (en) 2010-08-26
JP2010513260A (ja) 2010-04-30
CN101652371A (zh) 2010-02-17
EP2102213A1 (en) 2009-09-23
RU2009126774A (ru) 2011-01-20
GB0624880D0 (en) 2007-01-24
MX337864B (es) 2016-03-23
CN102391271B (zh) 2015-12-09
WO2008072018A1 (en) 2008-06-19
JP2011201906A (ja) 2011-10-13
ZA200904317B (en) 2010-08-25
MX2009006283A (es) 2009-10-12
NO20092503L (no) 2009-08-27
JP4786748B2 (ja) 2011-10-05
RU2422445C2 (ru) 2011-06-27
CA2672644A1 (en) 2008-06-19
US20080146601A1 (en) 2008-06-19
US7851482B2 (en) 2010-12-14
AU2007331223A1 (en) 2008-06-19
CN102391271A (zh) 2012-03-28

Similar Documents

Publication Publication Date Title
BRPI0720232A2 (pt) Produto de cloridrato de oximorfona, formulação farmacêutica, método para purificar cloridrato de oximorfona, e, produto de cloridrato de oximorfona
IL185804A0 (en) Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments
ZA200903160B (en) Sulfonyl-Phenyl-2H-[1,2,4]Oxodiazol-5-one Derivatives, Processes for their preparation and their use as pharmaceuticals
IL193340A0 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
BRPI0501367B1 (pt) sistema de entrega de produto-em-demanda para produto agrìcola
FI20070521A0 (fi) Rakeita, tabletteja ja rakeistusmenetelmä
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
IL192845A (en) The history of benzamide and the trower, a process for making them and their pharmaceutical preparations
IL242028A0 (en) A system for dispensing doses of medicine operated by means of a micro-pump
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
BRPI0815091A2 (pt) Método e sistema para determinar a autenticidade de um produto farmacêutico.
NO20091424L (no) Substituerte amider, fremgangsmåte for fremstilling derav og anvendelse derav
BRPI0808034A2 (pt) Método para produzir hidrocloreto de prasugrel, hidrocloreto de prasugrel, composição farmacêutica, e, uso de um hidrocloreto de prasugrel.
BRPI1014865A2 (pt) "composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica"
BRPI0820898A2 (pt) Método, produto de programa de computador, e, sistema
IL195245A0 (en) Substituted prolinamides, production thereof and their use as drugs
BRPI0820008A2 (pt) Sistema e método para produção de grânulos
EP2018872A4 (en) PHARMACEUTICAL PRODUCT
BRPI0716452A2 (pt) Sistemas não destrutivos, dispositivos, e métodos para avaliar dispositivos de distribuição de medicamentos de iontoforese
PL1856988T3 (pl) Sposób wytwarzania i stosowania wyrobów z dodatkiem cukru flawonoidowego
GB0614586D0 (en) Pharmaceutical Formulation
BRPI0905790A2 (pt) 'micropartícula, método para a fabricação de micropartícula e preparação farmacêutica
IL193339A0 (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
IL193341A0 (en) Novel azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
BRPI0811134A2 (pt) Método para reduzir cardiotoxicidade e/ou melhorar a sobrevivência de quimioterapia com antraciclina, e, composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2468 DE 24/04/2018 POR TER SIDO INDEVIDA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL